Form 4: Apogee Therapeutics CEO Sells Shares Under 10b5-1 Plan

Apogee Therapeutics CEO Michael Henderson reported the sale of 19,000 shares of common stock for approximately $1.5 million, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, Chief Executive Officer and Director of Apogee Therapeutics, Inc. (APGE), reported the sale of 19,000 shares of common stock.
• The transactions occurred on March 11, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
• The shares were sold in three separate transactions at weighted average prices of $74.29, $74.83, and $75.86.
• The total value of the shares sold is approximately $1,495,778.92.
• Following these transactions, Mr. Henderson beneficially owns 1,152,987 shares of Apogee Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral. While insider selling can be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns that the sale is based on new, adverse information.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not based on new, non-public information.

Negatives

• Insider selling, even if planned, can sometimes be perceived by the market as a signal of reduced confidence in the company's near-term growth prospects.
• The CEO sold a significant number of shares, totaling 19,000.

Risks

• Investor sentiment could be negatively impacted by the perception of insider selling, potentially leading to short-term stock price volatility.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the execution of a pre-arranged trading plan.

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a Rule 10b5-1 plan, are closely monitored by investors. While 10b5-1 plans are designed to allow insiders to sell shares without possessing material non-public information, significant sales by a CEO can still influence market perception, especially in the biotechnology sector where company-specific news heavily impacts stock performance.

Stakeholder Impact

• Shareholders may interpret the CEO's sale of shares as a potential signal, though the 10b5-1 plan provides a pre-planned context.

Key Dates

Recommendation

The sale by CEO Michael Henderson, while significant, was conducted under a Rule 10b5-1 trading plan established well in advance. This suggests the transaction is for personal financial planning rather than a reaction to new company-specific information. Therefore, a seasoned investor would likely maintain a 'hold' position, awaiting further operational or financial updates from Apogee Therapeutics before adjusting their stance.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Stock Sale, CEO, Michael Henderson, 10b5-1 Plan, Equity Transaction